This is supported by a clinical study in which aspirin therapy appeared to favor an overall antiangiogenic balance in women with breast cancer who received tamoxifen as assessed by decreasing plasma VEGF levels and thrombin receptor mediated release of TSP-1 and VEGF from platelets [110]. Here, VEGFA is linked to breast cancer.